Hims & Hers
Program terms need a fresh check
Edited by Designing Longevity Editorial · earlier profile checked May 1, 2026
Current program terms need a fresh check. Request a written care and medication quote. Earlier public-record dates are shown below.
Reviews of individual programs
Program reviews cover their own costs, terms and support. The program-terms checklist applies to the named care program, not every service offered by this company.
Hims GLP-1 program reviewProgram costs and payment terms
Current program terms need a fresh check. Get a written price and billing quote directly before paying.
- Membership
- Current membership price needs a fresh check.
- Insurance
- Insurance terms need a fresh check; confirm directly before paying.
Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.
The full profile and rubric were last checked May 1, 2026. Current commercial terms above have their own check date; they do not refresh earlier ratings or clinical claims.
Read the earlier full profile and source record (May 1, 2026)
This record keeps its original check dates. The program-terms checklist above covers costs, billing and advertised support for the named care program.
Earlier editorial take
Look elsewhere if
Users who want labs ordered before a GLP-1 prescription
Hims uses async intake without baseline labs before prescribing. If you want pre-treatment labs, this is not the model.
Our take
If you specifically want a brand-name GLP-1 from a public-company telehealth platform with mature compliance infrastructure, post-settlement Hims is a credible option, especially for the new oral Wegovy pill. The honest counterweight: the September 2025 FDA warning letters and the messy 2025 break with Novo Nordisk are both recent enough that we are docking the score below where a clean operator would land. Trustpilot at 3.0/5 with 28% one-star reviews is worse than Ro's, and the BBB A+ does not fully offset that.
Pros
- Public company (NYSE: HIMS) with SEC-grade financial disclosure
- BBB Accredited since 2018 with A+ rating, strongest in our cohort
- Authorized distributor for Novo Nordisk Wegovy, oral Wegovy pill, and Ozempic post-settlement
Cons
- Twin FDA warning letters Sept 9, 2025 on compounded-semaglutide marketing claims
- Messy 2025 break with Novo Nordisk over compounding before March 2026 settlement
- Trustpilot 3.0/5 with 28% one-star reviews across roughly 8,000 reviews
- No compounded GLP-1 option for new patients post-settlement
- Async-only consultations; no labs ordered before prescribing
Pricing
Current pricing needs a fresh check.
Turnaround
Same-day Rx after async intake
States served
All 50
Earlier full review checked
May 1, 2026
Earlier rubric breakdown
How the earlier rating was scoredLicensure
20% weightLicense and enforcement records checked at the profile verification date.
Active 50-state telehealth licensure as a publicly-traded company with mature compliance infrastructure. Counterweight: twin FDA warning letters dated September 9, 2025 directly to Hims & Hers Health Inc. (dba Hims and dba Hers) cited false or misleading claims on compounded semaglutide marketing. Recency is the issue here, the warning letters are eight months old at capture date and weighed against the operating-license signal.
Evidence checked in the earlier review (4)
Hims & Hers Health, Inc. (NYSE: HIMS) operating entity
Business filingPublicly-traded under ticker HIMS; SEC filings are public. Founded 2017, IPO via SPAC merger in January 2021.
Checked May 1, 2026
FDA Warning Letter to Hims & Hers Health Inc. dba Hims (CMS #716567)
Federal enforcementDated September 9, 2025. FDA cited claims like "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients" as false or misleading under sections 502(a) and 502(bb) of the FD&C Act, because compounded drugs are not FDA-approved and cannot be marketed as equivalent to the brand-name approved products.
Checked May 1, 2026 · source
FDA Warning Letter to Hims & Hers Health Inc. dba Hers (CMS #716825)
Federal enforcementCompanion warning letter to the Hers brand, also dated September 9, 2025, on the same compounded-semaglutide marketing claims.
Checked May 1, 2026 · source
Active 50-state licensure
State licensureHims operates in all 50 states via a network of licensed independent clinicians.
Checked May 1, 2026
Accreditation
20% weightAccreditation records checked at the profile verification date.
BBB Accredited Business since February 22, 2018 with an A+ rating, the strongest BBB posture in our cohort. LegitScript certification is inferred (Hims advertises on Google and Meta, which require it) but not independently confirmable on a public registry, since LegitScript does not publish a per-merchant directory.
Evidence checked in the earlier review (2)
BBB Accredited since February 22, 2018, A+ rating
AccreditationHims & Hers Inc. (San Francisco) is the BBB-accredited entity. A+ is the strongest BBB rating in our cohort.
Checked May 1, 2026 · source
LegitScript Healthcare Merchant Certification
AccreditationInferred from active Google and Meta advertising (which requires LegitScript), but LegitScript does not publish a public per-merchant directory we could confirm against.
Checked May 1, 2026 · source
Transparency
20% weightPublished testing, sourcing, and formulation information.
As a publicly-traded company, Hims has stronger baseline disclosure than private competitors (SEC filings, earnings calls, audited financials).
Evidence checked in the earlier review (1)
Public-company SEC filings
Financial transparencyNYSE: HIMS. Quarterly 10-Qs and annual 10-K are public. This is unusual disclosure depth in our cohort.
Checked May 1, 2026
Product quality
15% weightPublished testing, recall, and supply-chain information.
This earlier product-quality score has not been refreshed. The commercial update does not recheck manufacturing, sourcing or clinical care.
Evidence checked in the earlier review (3)
Branded GLP-1 supply via authorized distribution
SourcingWegovy injection, oral Wegovy pill, and Ozempic dispensed through Novo Nordisk authorized distribution post March 2026 settlement.
Checked May 1, 2026 · source
No FDA recalls on Hims-distributed branded GLP-1
Recall historyChecked May 1, 2026 · source
Prior compounded-marketing posture (now corrected)
Vendor/marketing oversightTwin FDA warning letters Sept 9, 2025 cited misleading marketing on then-current compounded semaglutide. The company has since wound down compounded GLP-1 advertising under the March 2026 settlement, but the warning letters are recent enough to weigh.
Checked May 1, 2026 · source
Pricing
15% weightValue within the category, no surprise fees, refund policy.
Current pricing needs a fresh check.
Customer service
10% weightRefund policy, support quality, complaint history.
Mixed external review picture: BBB rates A+ with accreditation since 2018 (strong), Trustpilot is 3.0/5 across roughly 8,000 reviews with 28% one-star (weak). The split is real and large enough to weigh down this score. Top recurring negatives across platforms: cancellation friction, surprise charges, async-only consultations with no labs ordered before prescribing.
Evidence checked in the earlier review (3)
BBB A+ rating, accredited since February 22, 2018
Complaint historyA+ is the strongest BBB rating in our cohort. Long-tenured accreditation is itself a positive signal.
Checked May 1, 2026 · source
Trustpilot rating: 3.0/5 across roughly 8,000 reviews
External review40% 5-star, 28% 1-star at capture date. The bimodal distribution is itself a signal: a large slice of users is genuinely unhappy.
Checked May 1, 2026 · source
Async-only consultations, no labs before prescribing
Care modelTelehealth-typical: synchronous video is not standard, and labs are not ordered before issuing a GLP-1 prescription.
Checked May 1, 2026
Public reviews
What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.
Trustpilot
3.0/5 across roughly 8,000 reviews. Distribution is bimodal: 40% 5-star, 28% 1-star. Negatives concentrate on cancellation friction, surprise charges, and difficulty unsubscribing. Positives concentrate on convenience and visible results.
Better Business Bureau
BBB Accredited since February 22, 2018; current rating A+. The complaint themes mirror Trustpilot (cancellation, refund processing, unauthorized charges) but the company has been responsive enough to maintain A+ accreditation, which is the strongest BBB posture in our cohort.
ConsumerAffairs
Recurring negative themes: misleading sign-up flow, automatic refill structure, prepaid annual billing. The pattern matches Trustpilot rather than the BBB complaint resolution view.
Regulatory & legal history
FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.
- FDA Warning LetterSeptember 9, 2025
FDA issued warning letter (CMS #716567) to Hims & Hers Health Inc. dba Hims, citing claims like "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients" on the compounded-semaglutide product page as false or misleading under sections 502(a) and 502(bb) of the FD&C Act. Compounded drugs are not FDA-approved and cannot be marketed as equivalent to brand-name approved products. Hims was given 15 working days to respond.
Source - FDA Warning LetterSeptember 9, 2025
Companion FDA warning letter (CMS #716825) to Hims & Hers Health Inc. dba Hers, on the same compounded-semaglutide marketing claims. Issued the same day.
Source - Lawsuit FiledJune 22, 2025
Novo Nordisk terminated its April 2025 collaboration with Hims & Hers, citing concerns about Hims's continued mass compounding of semaglutide and what Novo described as deceptive marketing of compounded copycats of Wegovy.
Source - SettlementMarch 9, 2026
Novo Nordisk and Hims & Hers reached a settlement: Novo dropped its lawsuit and Hims became an authorized seller of Wegovy (injection and oral pill) and Ozempic. As part of the deal, Hims agreed to stop advertising compounded GLP-1 medications. This resolved the prior 2025 dispute and reset the commercial relationship.
Source
What to expect
- 1
Pharmacy fulfillment via authorized distribution
3-7 daysApproved Rx for branded Wegovy or Ozempic routes through authorized pharmacy distribution. Cold-chain shipping for injections; the oral Wegovy pill ships standard.
Accreditations
State pharmacy/clinic license
Verified · May 1, 2026
LegitScript Certified
Unverified · May 1, 2026 · source
Frequently asked
What does Hims & Hers charge for membership?
Current membership price needs a fresh check.
Does Hims & Hers accept insurance?
Insurance terms need a fresh check; confirm directly before paying.
Is Hims BBB-accredited?
Yes. Hims & Hers Inc. (San Francisco) has been BBB Accredited since February 22, 2018 with an A+ rating, the strongest BBB posture in our cohort. The profile is at https://www.bbb.org/us/ca/san-francisco/profile/health-and-medical-products/hims-hers-inc-1116-880029. Long-tenured A+ accreditation is itself a positive signal even though Trustpilot reviews are weaker.
Why is the Trustpilot score so much lower than the BBB rating?
Trustpilot is 3.0/5 across roughly 8,000 reviews with 28% one-star ratings, while BBB is A+ accredited since 2018. The two platforms measure different things. BBB ratings reflect complaint resolution behavior over time, where Hims is responsive enough to maintain A+. Trustpilot reflects what individual customers post, where the most upset users dominate. Both are real signals; we weigh them both. The recurring Trustpilot negatives match BBB complaint themes (cancellation friction, surprise charges).
Update history
Every meaningful change to this profile, with a date stamp. We don't silently re-score.
- May 1, 2026
Initial published profile. Sources HEAD-checked at publish time. Score (3.4) reflects the trade-off between strong baseline signals (public-company disclosure, BBB A+ since 2018, post-settlement branded-only supply chain) and meaningful negatives (twin FDA warning letters Sept 2025, Trustpilot 3.0/5 with 28% one-star, recurring billing-friction complaints). The March 2026 Novo settlement is recent enough that we may revisit the score in a future review window.
Compare Hims & Hers head-to-head
Compare dated terms, public records and the questions still needing verification.
Edited by Designing Longevity Editorial. Earlier profile checked May 1, 2026.
Spot something out of date or wrong? Let us know and we'll re-check.
Back to all providers